Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000 Jan;47(1):127-31
Date
01/13/2000Pubmed ID
10632113Scopus ID
2-s2.0-0033960042 (requires institutional sign-in at Scopus site) 51 CitationsAbstract
We sought to determine whether combinations of glatiramer acetate and parenteral or ingested type I interferon were synergistic in experimental autoimmune encephalomyelitis. Glatiramer acetate, subcutaneous murine interferon-alpha, or ingested murine interferon-alpha individually improved clinical scores. In contrast, glatiramer acetate in conjunction with either subcutaneous or ingested interferon-alpha did not improve clinical scores compared with control. These data suggest that clinical trials designed to test a possible synergistic effect of glatiramer acetate and type I interferon in humans should be designed to detect possible adverse effects of this combination of immunomodulatory agents.
Author List
Brod SA, Lindsey JW, Wolinsky JSMESH terms used to index this publication - Major topics in bold
AnimalsDose-Response Relationship, Drug
Drug Therapy, Combination
Encephalomyelitis, Autoimmune, Experimental
Glatiramer Acetate
Immunosuppressive Agents
Interferon Type I
Mice
Peptides